TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
An analysis of prospectively logged menstrual cycles found that users of a combined GLP-1/GIP receptor agonist had a larger average reduction in cycle length and lower cycle variability than comparison groups. The study found stronger differences among participants with polyendocrine metabolic ovarian syndrome, but it does not establish that the drugs caused the changes.
An analysis of a prospective U.S. cohort found that women reporting use of a combined GLP-1/GIP receptor agonist had a greater reduction in menstrual-cycle length and lower cycle variability than women using GLP-1 drugs or no incretin medication. The results, presented at the American Society for Reproductive Medicine annual meeting, show an association, not proof that the medication caused more regular cycles.
Shruthi Mahalingaiah, MD, MS, of the Harvard T.H. Chan School of Public Health and colleagues analyzed 1,945 participants who logged 70,134 menstrual cycles in the Apple Women’s Health Study. Of the participants, 123 reported taking a combined GLP-1/GIP drug in the past year, 258 reported taking a GLP-1 medication, and 1,564 had never used either type, according to the report.
Mean cycle length fell by 2.5 days among combined-drug users, compared with 0.4 days among GLP-1 users and 0.8 days among never-users. Mean individual cycle variability was 6.93 days for combined-drug users, 7.45 days for GLP-1 users and 7.46 days for never-users. These are the study’s reported group results; the source does not provide a treatment-versus-control estimate that would establish a drug effect.
In a subgroup with polyendocrine metabolic ovarian syndrome (PMOS), the reported mean cycle variability was 5.80 days among combined-drug users, 7.34 days among GLP-1 users and 9.45 days among never-users. The researchers said participants were younger than 50, were not pregnant or lactating or using hormones, had recorded at least three cycles, and had cycle lengths between 10 and 90 days. Medication use and medical history were collected through surveys, while menstrual records were shared from Apple HealthKit; the researchers did not use sensor data.
Why Cycle Changes Matter
The findings could matter to people whose irregular cycles are linked with metabolic conditions, including PMOS, and to clinicians monitoring menstrual health during weight-loss treatment. Irregular periods can be relevant beyond fertility: reproductive endocrinologist Rachel Weinerman told MedPage Today they can also signal underlying health issues. But this analysis does not show whether the observed differences translate into improved ovulation, fertility outcomes or other health benefits.
Menstrual changes may also be useful to study as a possible effect of incretin medicines, which are used for metabolic and weight-related reasons. Mahalingaiah said the drugs could affect ovulatory health through broader metabolic changes or possible direct ovarian effects. Those are proposed explanations, not mechanisms demonstrated by this cohort analysis.
Products Worth Considering
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Garmin Forerunner 165 GPS Running Smartwatch, 43 mm, Black
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
As an affiliate, we earn on qualifying purchases.
How Researchers Tracked Cycles
The Apple Women’s Health Study is a longitudinal digital cohort of about 147,000 U.S. women who prospectively log menstrual cycles. The analysis focused on a smaller eligible group and compared participants who said they had used GLP-1 or combined GLP-1/GIP medicines during the prior year with those who had not. The groups had similar baseline characteristics overall, but medication users were older on average and had higher proportions of PMOS, infertility, type 2 diabetes and hypertension than never-users.
The report describes the work as a prospective cohort analysis presented at the ASRM annual meeting. It notes that earlier retrospective studies had suggested a possible association with menstrual regularity, while this research examined cycle length and variability using prospectively logged records. The only FDA-approved combined GLP-1/GIP drug identified in the report is tirzepatide, marketed as Zepbound. The analysis grouped medication use and does not provide results broken down by individual drug.
“This more pronounced reduction among PMOS individuals might suggest a separate pathway that might focus on ovulatory health in addition to those metabolic parameters that support ovulation, but further research is necessary.”
— Shruthi Mahalingaiah, Harvard T.H. Chan School of Public Health
What the Cohort Cannot Establish
The study was observational, so differences between medication groups may reflect factors other than drug use. The report notes that users differed from never-users in age and in the prevalence of several health conditions. It does not establish whether the medicines themselves changed cycles, whether weight loss accounted for any association, or whether another factor was involved.
The analysis also relied on self-reported medication use and did not report results by specific agent. The source gives group averages but does not state whether participants’ cycle changes were clinically meaningful or how long any changes lasted. It remains unclear whether the reported differences correspond to changes in ovulation, fertility or longer-term health outcomes.
Further Drug-Specific Results Ahead
Mahalingaiah said future manuscripts will break down the data by individual medications. Further research is also needed to test whether the associations hold in other populations and to distinguish possible medication effects from weight change and underlying conditions. The report does not give a timetable for those publications or describe a planned trial.
Key Questions
Did the study prove that incretin drugs make periods more regular?
No. It found an association between reported medication use and changes in cycle length and variability. An observational cohort cannot show that the drugs caused those changes.
Which medication group had the largest reported changes?
Participants reporting a combined GLP-1/GIP receptor agonist had the largest mean reduction in cycle length: 2.5 days, compared with 0.4 days for GLP-1 users and 0.8 days for never-users.
What did the study find among participants with PMOS?
Mean cycle variability was reported as 5.80 days among combined-drug users, 7.34 days among GLP-1 users and 9.45 days among never-users in the PMOS subgroup. The results do not establish why the groups differed.
Does the report show which specific drug produced the results?
No. The analysis grouped participants by medication type and did not report results for individual drugs. Mahalingaiah said future publications are expected to break down the data by specific agents.
Source: medpagetoday.com
